Interfering with interferons in inflammatory bowel disease
Authors:
- S GhoshSGS Ghosh
- R ChaudharyRCR Chaudhary
- M CarpaniMCM Carpani
- R PlayfordRPR Playford
Abstract
Early experience of fontolizumab, a humanised anti‐interferon γ antibody, in active Crohn's disease has shown that the drug caused a significant decrease in endoscopic severity scores and CRP and was reasonably well tolerated. Fontolizumab may be worthy of further clinical trialsKeywords
This publication has 22 references indexed in Scilit:
- A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s diseaseGut, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Fontolizumab, a humanised anti-interferon antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's diseaseGut, 2005
- Review: Milstein Award Lecture: Interferons and Cancer: Where from Here?Journal of Interferon & Cytokine Research, 2005
- Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled TrialClinical Gastroenterology and Hepatology, 2005
- IL-23 drives a pathogenic T cell population that induces autoimmune inflammationJournal of Experimental Medicine, 2005
- Interleukin-17 Family Members and InflammationImmunity, 2004
- A randomised placebo controlled trial of pegylated interferon α in active ulcerative colitisGut, 2003
- Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating studyGut, 2003
- Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss.Alimentary Pharmacology & Therapeutics, 1996